AngioDynamics Stock Earnings Estimates Cut by HC Wainwright

AngioDynamics, Inc. (NASDAQ:ANGO) – HC Wainwright lowered their Q2 2027 earnings per share estimates for shares of AngioDynamics in a research report issued on Tuesday, October 13th. HC Wainwright analyst Y. Chen now forecasts that the medical instruments supplier will earn ($0.11) per share for the quarter, down from their prior estimate of ($0.10). HC Wainwright currently has a “Buy” rating and a $18.00 target price on the stock. The consensus estimate for AngioDynamics’ current full-year earnings is ($0.25) per share. HC Wainwright also issued estimates for AngioDynamics’ Q3 2027 earnings at ($0.10) EPS, Q4 2027 earnings at ($0.02) EPS, FY2027 earnings at ($0.28) EPS, Q1 2028 earnings at ($0.09) EPS, Q2 2028 earnings at ($0.05) EPS, Q3 2028 earnings at ($0.02) EPS, Q4 2028 earnings at $0.02 EPS and FY2028 earnings at ($0.15) EPS.

A number of other research analysts have also recently issued reports on ANGO. Wall Street Zen cut AngioDynamics from a “buy” rating to a “hold” rating in a report on Saturday, October 10th. Zacks Research raised shares of AngioDynamics from a “strong sell” rating to a “hold” rating in a report on Monday, October 5th. Canaccord Genuity Group reiterated a “buy” rating and set a $20.00 target price on shares of AngioDynamics in a research report on Friday, October 9th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of AngioDynamics in a research report on Friday, July 17th. One analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $19.00.

AngioDynamics Price Performance

Shares of NASDAQ:ANGO opened at $11.05 on Thursday. The business’s fifty day moving average price is $15.08 and its two-hundred day moving average price is $13.12. AngioDynamics has a fifty-two week low of $9.39 and a fifty-two week high of $16.29. The stock has a market capitalization of $464.65 million, a price-to-earnings ratio of -14.17 and a beta of 0.30.

AngioDynamics (NASDAQ:ANGO) last posted its earnings results on Thursday, October 8th. The medical instruments supplier reported ($0.04) EPS for the quarter, topping the consensus estimate of ($0.11) by $0.07. The business had revenue of $80.92 million during the quarter, compared to the consensus estimate of $80.51 million. AngioDynamics had a negative return on equity of 4.49% and a negative net margin of 10.12%. AngioDynamics has set its FY 2027 guidance at -0.290–0.240 EPS.

Hedge Funds Weigh In On AngioDynamics

Several institutional investors have recently bought and sold shares of ANGO. Integrated Wealth Concepts LLC bought a new stake in shares of AngioDynamics during the second quarter valued at approximately $38,000. Legal & General Group Plc acquired a new stake in shares of AngioDynamics in the second quarter valued at approximately $45,000. Public Employees Retirement System of Ohio acquired a new stake in shares of AngioDynamics in the second quarter valued at approximately $64,000. Arrowstreet Capital Limited Partnership raised its position in AngioDynamics by 0.7% in the 1st quarter. Arrowstreet Capital Limited Partnership now owns 758,450 shares of the medical instruments supplier’s stock worth $8,624,000 after purchasing an additional 5,509 shares during the last quarter. Finally, State of Wyoming bought a new position in AngioDynamics in the 2nd quarter worth approximately $72,000. Institutional investors own 89.43% of the company’s stock.

Insider Activity at AngioDynamics

In related news, SVP Warren Jr sold 23,370 shares of the stock in a transaction that occurred on Thursday, July 30th. The stock was sold at an average price of $14.72, for a total transaction of $344,006.40. Following the sale, the senior vice president directly owned 64,745 shares in the company, valued at $953,046.40. This represents a 26.52% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 6.00% of the stock is owned by insiders.

More AngioDynamics News

Here are the key news stories impacting AngioDynamics this week:

• Positive Sentiment: HC Wainwright’s $18 target implies substantial upside from the recent $11.05 reference price, and the firm continues to recommend buying AngioDynamics shares. HC Wainwright Has Lowered Expectations for AngioDynamics Stock Price
• Positive Sentiment: The analyst’s longer-term outlook points to improving results: projected losses narrow from $0.28 per share in fiscal 2027 to $0.15 in fiscal 2028, with a projected return to quarterly profitability of $0.02 per share in the fourth quarter of fiscal 2028.
• Neutral Sentiment: HC Wainwright forecasts fiscal 2028 quarterly EPS of ($0.09), ($0.05), ($0.02), and $0.02, respectively. The estimates suggest gradual progress but imply AngioDynamics is not expected to be profitable for the full fiscal year.
• Negative Sentiment: HC Wainwright reduced its fiscal 2027 EPS forecast to a loss of $0.28 from $0.27 and cut estimates for the second quarter of fiscal 2027 to a $0.11 loss from $0.10, the third quarter to a $0.10 loss from $0.06, and the fourth quarter to a $0.02 loss from a prior $0.01 profit. These revisions indicate weaker near-term earnings expectations.
• Negative Sentiment: The firm also lowered its price target from $19 to $18, even while retaining its Buy rating. The target reduction may limit enthusiasm, although the revised objective still indicates meaningful potential appreciation. Benzinga and The Fly analyst update

About AngioDynamics

AngioDynamics, Inc is a medical device company that develops, manufactures and markets minimally invasive products for use in vascular disease, vascular access and oncology. Its technologies are designed to help physicians treat blood clots, restore blood flow, manage vascular access and ablate targeted tissue.

The company’s portfolio includes the Auryon platform for atherectomy, which uses laser technology to treat peripheral arterial disease; the AngioVac and AlphaVac systems for removing thrombus and other unwanted material from blood vessels; and BioSentry products used to seal biopsy tracts.